{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:31:19Z","timestamp":1790800279500,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy of probiotics in the treatment of metabolic-associated fatty liver disease (MAFLD) mainly in terms of liver function, glucose and lipid metabolism, and inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RCTs were searched on PubMed, Web of Science, Embase, and the Cochrane Library until June 2022.\u00a0A meta-analysis was performed on the therapeutic efficacy of probiotics on liver function, glucose and lipid metabolism, and inflammatory biomarkers by using RevMan 5.4 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 772 patients from 15 studies were included in the analysis. The methodological quality varied across studies. We found that adding probiotic therapies could reduce the levels of alanine aminotransferase [mean difference (MD): \u221211.76 (\u221216.06, \u22127.46), p\u00a0&amp;lt;\u00a00.00001], aspartate aminotransferase (MD: \u22129.08 (\u221213.60, \u22124.56), p &amp;lt; 0.0001], \u03b3-glutamyltransferase [MD: \u22125.67 (\u22126.80, \u22124.54), p\u00a0&amp;lt;\u00a00.00001] and homeostasis model assessment\u2013insulin resistance [MD: \u22120.62 (\u22121.08, \u22120.15), p = 0.01], in patients with MAFLD compared with those in control individuals. However, there was no statistically significant improvement in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, C-reactive protein and tumor necrosis factor \u03b1 among patients with MAFLD. Subgroup analyses showed that other key factors, such as age, participants\u2019 baseline body mass index, and the duration of intervention, may influence probiotic therapy outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is promising evidence that probiotic supplementation can reduce liver enzyme levels and regulate glycometabolism in patients with MAFLD. Further rigorous and long-term trials exploring these novel therapeutic perspectives are warranted to confirm these results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1014670","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T13:40:13Z","timestamp":1667482813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiuhong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","article-title":"Gut microbiota:novel therapeutic target for nonalcoholic fatty liver disease","volume":"13","author":"Suk","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1731704","article-title":"Management of obesity and nonalcoholic fatty liver Disease:A literature review","volume":"41","author":"Hashem","year":"2021","journal-title":"Semin Liver Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16183415","article-title":"NAFLD and extra-hepatic Comorbidities:Current evidence on a multi-organ metabolic syndrome","volume":"16","author":"Rosato","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two\"hits\"","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/PHMT.S188989","article-title":"Pediatric non-alcoholic fatty liver disease: Current perspectives on diagnosis and management","author":"Di Sessa","year":"2019","journal-title":"Pediatr Health Med Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13622","article-title":"Mitochondria, oxidative stress and nonalcoholic fatty liver disease:A complex relationship","volume":"52","author":"Karkucinska-Wieckowska","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8507583","article-title":"Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease","volume":"2019","author":"Aragon\u00e8s","year":"2019","journal-title":"BioMed Res Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5985.21.02896-5","article-title":"Gut microbiota and non-alcoholic fatty liver disease","volume":"67","author":"Abenavoli","year":"2021","journal-title":"Minerva Gastroenterol (Torino)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101124","article-title":"Gut microbiota and nonalcoholic fatty liver disease: Insights on mechanisms and therapy","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic fatty liver Disease:Modulating gut microbiota to improve severity","volume":"158","author":"Aron-Wisnewsky","year":"2020","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093066","article-title":"The molecular and mechanistic insights based on gut-liver Axis:Nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement","volume":"21","author":"Ji","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126485","article-title":"Nonalcoholic fatty liver disease (NAFLD) as model of gut-liver axis interaction: From pathophysiology to potential target of treatment for personalized therapy","volume":"22","author":"Fianchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1037\/met0000197","article-title":"The effect of publication bias on the q test and assessment of heterogeneity","volume":"24","author":"Augusteijn","year":"2019","journal-title":"Psychol Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B20","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin,and glycemic parameters in non-alcoholic fatty liver Disease:A randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters,liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease:A randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial","author":"Javadi","year":"2017","journal-title":"Iranian Red Crescent Med J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Digestive Dis Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP\u00ae BCMC\u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10018-1226","article-title":"Probiotic therapy in patients with nonalcoholic steatohepatitis in Zagazig University Hospitals","volume":"7","author":"Abdel Monem","year":"2017","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver Disease:A double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.567654","article-title":"Microbial Metabolites:Critical regulators in NAFLD","volume":"11","author":"Dai","year":"2020","journal-title":"Front Microbiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/children4080066","article-title":"Gut-liver axis derangement in non-alcoholic fatty liver disease","volume":"4","author":"Poeta","year":"2017","journal-title":"Children (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101124","article-title":"Gut microbiota and nonalcoholic fatty liver disease: Insights on mechanisms and therapy","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8848","DOI":"10.1038\/s41598-020-65051-8","article-title":"Gut metabolites and inflammation factors in non-alcoholic fatty liver disease:A systematic review and meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-017-1568-y","article-title":"Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes:a systematic review and meta-analysis","volume":"57","author":"Khalesi","year":"2018","journal-title":"Eur J Nutr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.844242","article-title":"Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver Disease:An umbrella of systematic review and meta-analysis","volume":"9","author":"Musazadeh","year":"2022","journal-title":"Front Nutr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1479164118813890","article-title":"Impact of race\/ethnicity on insulin resistance and hypertriglyceridaemia","volume":"16","author":"Raygor","year":"2019","journal-title":"Diabetes Vasc Dis Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/01.mco.0000172574.64019.98","article-title":"Insulin resistance: sex matters","volume":"8","author":"Mittendorfer","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: The effects of probiotics in nonalcoholic fatty liver disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: A systematic review,meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease:a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/2277-9175.176368","article-title":"Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver","volume":"5","author":"Foroughi","year":"2016","journal-title":"Adv BioMed Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12876-019-1055-4","article-title":"Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial","volume":"19","author":"Saadati","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver diseas-a systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12671","article-title":"Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials","volume":"46","author":"Gao","year":"2016","journal-title":"Hepatol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7888076","article-title":"Effect of probiotics therapy on nonalcoholic fatty liver disease","author":"Huang","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2016391","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12866-016-0708-5","article-title":"Age-related changes in gut microbiota composition from newborn to centenarian:a cross-sectional study","volume":"16","author":"Odamaki","year":"2016","journal-title":"BMC Microbiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2020.111095","article-title":"Gut microbiota and old age: Modulating factors and interventions for healthy longevity","volume":"141","author":"Coman","year":"2020","journal-title":"Exp Gerontol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac8469","article-title":"Gut microbiota and aging.","author":"O'Toole","year":"2015","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2061-5","article-title":"Gut microbiota and obesity","volume":"73","author":"G\u00e9rard","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-020-0607-6","article-title":"Profile of the gut microbiota of adults with obesity: A systematic review","volume":"74","author":"Crovesy","year":"2020","journal-title":"Eur J Clin Nutr"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: The effects of probiotics in nonalcoholic fatty liver disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1014670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T13:40:15Z","timestamp":1667482815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1014670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":61,"alternative-id":["10.3389\/fendo.2022.1014670"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1014670","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"article-number":"1014670"}}